Drug Profile
Oseltamivir - Roche
Alternative Names: EN 241104; GS 4104; GS 4104-002; Ke Wei; Kewei; Oseltamivir phosphate; RO 640796; RO 640796/002; Tamiflu; Tamiflu Dry SyrupLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Australian National University; Gilead Sciences; University of California at Berkeley
- Developer Chugai Pharmaceutical; HEC Pharm; Roche
- Class Acetamides; Antivirals; Cyclohexenes; Esters; Small molecules
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 02 Feb 2021 Launched for Influenza virus infections (In infants, In neonates) in Japan (PO)
- 23 Jul 2019 Sanofi acquire the exclusive over-the-counter (OTC) rights for oseltamivir in USA
- 28 Aug 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections(In adolescents, In children, In infants, In neonates) in Belgium (PO, Capsule)